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 2 
Abstract		
Genome-wide	 association	 studies	 (GWAS)	 have	 identified	 thousands	 of	 novel	 genetic	
associations	 for	 complex	 genetic	 disorders,	 leading	 to	 the	 identification	 of	 potential	
pharmacological	 targets	 for	 novel	 drug	 development.	 In	 schizophrenia,	 108	 conservatively	
defined	 loci	 that	 meet	 genome-wide	 significance	 have	 been	 identified	 and	 hundreds	 of	
additional	 sub-threshold	 associations	 harbor	 information	 on	 the	 genetic	 aetiology	 of	 the	
disorder.	In	the	present	study,	we	used	gene-set	analysis	based	on	the	known	binding	targets	of	
chemical	 compounds	 to	 identify	 the	 ‘drug	 pathways’	 most	 strongly	 associated	 with	
schizophrenia-associated	 genes,	 with	 the	 aim	 of	 identifying	 potential	 drug	 repositioning	
opportunities	 and	 clues	 for	 novel	 treatment	 paradigms,	 especially	 in	 multi-target	 drug	
development.	We	compiled	9,389	gene	sets	(2,496	with	unique	gene	content)	and	interrogated	
gene-based	p-values	from	the	PGC2-SCZ	analysis.	Although	no	single	drug	exceeded	experiment	
wide	 significance	 (corrected	p<0.05),	highly	 ranked	gene-sets	 reaching	 suggestive	 significance	
including	 the	 dopamine	 receptor	 antagonists	 Metoclopramide	 and	 Trifluoperazine	 and	 the	
tyrosine	 kinase	 inhibitor	Neratinib.	 This	 is	 a	 proof	 of	 principal	 analysis	 showing	 the	 potential	
utility	 of	 GWAS	 data	 of	 schizophrenia	 for	 the	 direct	 identification	 of	 candidate	 drugs	 and	
molecules	that	show	polypharmacy.		
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Introduction	
Schizophrenia	 is	a	common,	debilitating	neuropsychiatric	disorder	with	a	high	unmet	medical	
need.	Although	efficacious,	current	antipsychotics	are	not	 ideal	as	treatments	because	a	third	
of	patients	show	treatment	resistance,	and	approximately	another	third	respond	only	partially	
(Smith	 et	 al.	 2009).	 There	 has	 been	 no	 novel	 pharmacological	 treatment	 paradigm	 for	
schizophrenia	 for	 several	 decades,	 and	 new	 approaches	 are	 urgently	 needed	 (Hyman	 2012;	
Nutt	and	Need	2014;	Millan	et	al.	2015).	The	dopamine	D2	receptor	remains	the	primary	target	
of	 currently	 marketed	 multi-target	 antipsychotic	 drugs	 (Ginovart	 and	 Kapur	 2012),	 despite	
attempts	 to	 develop	 alternative	 treatment	 strategies.	 Most	 recent	 approaches	 to	 drug	
development	 in	 schizophrenia	 have	 focused	mainly	 on	 single-target	 drugs,	which	have	 so	 far	
failed	 in	 the	 clinic	 (Dunlop	 and	 Brandon	 2015).	 There	 is	 a	 growing	 realization	 that	 because	
binding	 of	 multiple	 receptor	 targets	 is	 characteristic	 of	 effective	 antipsychotics	 that	 new	
therapeutic	development	should	try	to	develop	drugs	which	also	show	“polypharmacy”,	(Wong	
et	 al.	 2010)	 and	 tools	 to	 improve	 the	 success	 of	 multi-target	 drug	 development	 (MTDD)	
approaches	will	be	important	(Carrieri	et	al.	2013).	
Support	for	the	multi-target	approach	to	drug	development	in	schizophrenia	comes	from	GWAS	
studies,	which	support	have	confirmed	that	schizophrenia	is	a	complex	genetic	disorder	with	a	
strong	polygenic	 component,	 from	hundreds	or	even	 thousands	of	 common	variants	of	 small	
effect,	as	well	as	rare	moderate-risk	variants	(Neale	and	Sklar	2015)	Specifically,	GWAS	meta-
analysis	 in	 schizophrenia	 by	 the	 Psychiatric	 Genomics	 Consortium	 (PGC)	 schizophrenia	 group	
has	 identified	128	 independent	 associations	 spanning	 that	meet	 genome-wide	 significance	 in	
108	genomic	 regions	notably	 including	 the	dopamine	D2	receptor	 locus,	but	also	many	other	
neurotransmitter	 genes,	 especially	 those	 involved	 in	 CNS	 calcium	 and	 glutamate	 signaling	
(Ripke	et	al.	2014).	 In	addition,	studies	have	also	utilized	sub-GWAS	significant	associations	to	
generate	polygenic	risk	scores,	thereby	allowing	the	profiling	of	genome-wide	risk	in	individuals	
and	across	neuropsychiatric	disorders	 (Purcell	 et	 al.	 2009),	 and	 to	 identify	neuronal,	 immune	
and	histone	biological	pathways	enriched	for	association	with	psychiatric	disorders	using	gene-
set	analyses	(O`Dushlaine	2015;	Harrison	2015).	
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In	 particular,	 this	 latter	 approach	 has	 the	 potential	 to	 drive	 forward	 new	 drug	 discovery	
paradigms,	beyond	the	identification	of	novel	individual	targets,	by	identifying	new	multi-target	
entities	 aimed	 at	 modulating	 schizophrenia	 associated	 pathways	 or	 disease	 networks.	
Alternatively,	 this	 approach	 could	 also	 be	 used	 to	 find	 indications	 for	 drug	 repositioning	 to	
generate	new	treatment	paradigms	for	schizophrenia,	via	matching	existing	clinical	compounds’	
binding	 profiles	 to	 targets	 or	 sets	 of	 targets	 generated	 from	GWAS	 or	 other	 genetic	 studies	
(Sanseau	et	al.	2012;	Grover	et	al.	2014).	 If	 compounds	already	known	to	be	safe	 in	man	 for	
other	 indications	 can	 be	 repositioned,	 they	 could	 be	 progressed	 more	 quickly	 and	 cheaply	
through	 human	 experimental	 medicine	 approaches	 aimed	 at	 providing	 proof-of-concept	 by	
clinical	validation	in	small	efficacy	studies.	Effective	compounds	can	then	be	further	refined	to	
develop	 novel	 effective	medications.	 In	 addition	 it	may	 provide	 leads	 for	MTDD	 approaches,	
which	are	difficult	to	prosecute	from	scratch,	because	of	the	difficulty	in	generating	structure-
activity	relationships	for	a	single	compound	aimed	at	multiple	targets.	Repositioning	in	this	way	
may	provide	a	head	start	for	MTDD	efforts.	
The	aim	of	the	current	study	is	to	identify	potential	drug	repositioning	opportunities	and	small	
molecule	 clues	 by	 leveraging	 genetic	 mega-analysis	 results	 for	 schizophrenia,	 utilizing	
knowledge	of	the	pharmacological	action	of	compounds	to	test	‘drug	pathways’	in	GWAS	data.	
Formally	this	is	a	gene-set	analysis	(GSA)	(Mooney	et	al.	2014)	where	instead	of	using	biological	
pathway	 information,	 gene-sets	 are	 defined	 on	 the	 basis	 of	 pharmacological	 profiles	 of	
chemical	compounds,	based	on	their	target	binding	affinities.	For	each	compound	a	drug	gene	
set	(DGS)	 is	composed	of	the	protein	targets	of	that	molecule,	which	meet	a	selected	binding	
threshold.	 Compounds	 which	 bind	 significant	 targets	 from	 within	 the	 GWAS	 data	 and	 show	
significant	statistical	association	as	a	DGS	and	could	be	considered	potential	multi-target	drugs	
for	that	disorder,	with	the	caveat	that	GWAS	data	is	agnostic	as	to	the	direction	of	effect	of	the	
drug	 as	 genetic	 pathway	 results	 lack	 direction	 of	 effect	 (O`Dushlaine	 2015).	 However,	 after	
suitable	expert	or	experimental	examination	candidate,	drugs	indicated	by	this	approach	drugs	
then	 be	 repositioned	 to	 the	 disorder	 under	 investigation	 if	 it	 is	 clinically	 approved,	 or	 may	
provide	 clues	 to	 novel	 treatment	 strategies	 in	multi-target	 drug	 development.	We	 present	 a	
proof	of	principle	analysis	applying	this	analytical	approach	to	schizophrenia	GWAS	data.	
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Materials	and	methods	
Genome	wide	filtered	(INFO	score	≥0.8	&	MAF	≥1%)	SNP	results	for	schizophrenia	were	taken	
from	the	PGC2	mega	analysis	(resulting	in	summary	statistics	for	7,865,159	variants)(Ripke	et	al.	
2014).	SNP	p-values	were	GC	corrected	prior	to	pathway	analysis	(Dadd	et	al.	2009).	Pathways	
sets	 were	 compiled	 using	 the	 ChEMBL	 database	 (v18,	 2014)	 (Bento	 et	 al.	 2014)	 containing	
ligands	with	an	activity	of	better	than	100	µM	against	proteins.	We	required	a	minimum	of	5	
genes	 per	 ligand	 in	 order	 to	 avoid	 bias	 in	 pathway	 analyses	 and	 in	 line	 with	 our	 aim	 to	
investigate	multi-drug	targets	in	schizophrenia.	This	resulted	in	9,389	pathways	of	which	2,496	
have	a	unique	gene	content.	Many	of	 the	drugs	nevertheless	had	very	 similar	 sets	of	 targets	
and/or	chemical	structures.	There	are	many	ways	to	address	this	but	we	choose	to	use	spectral	
decomposition	 of	 a	 2,496x2,496	 matrix	 of	 the	 Tanimoto	 similarity	 indices	 (Kristensen	 et	 al.	
2011)	using	 the	ECFP4	 fingerprint	 (Rogers	and	Hahn	2010)	of	 the	drugs	and	 small	molecules.	
We	 ascertained	 the	 number	 of	 independent	 tests	 performed	 as	 417.85	 for	 multiple	 testing	
corrections	 (http://neurogenetics.qimrberghofer.edu.au/matSpDlite/matSpDlite.R	 (Cheverud	
2001;	Nyholt	2004;	Li	and	Ji	2005)	setting	the	5%	significance	threshold	to	p=0.0001196.		
We	 used	 FORGE	 to	 combine	 p-values	 per	 gene	 and	 subsequently	 pathways	 (Pedroso	 et	 al.	
2012;	 Pedroso	 et	 al.	 2015).	 In	 order	 to	 combine	 SNP	 p-values	 per	 gene	 (Forge.pl)	 we	 set	 a	
maximum	of	1,000,000	permutations	and	the	algorithm	was	run	with	a	fuzzy	border	option	(5’	
35kb,	 3’	 10kb)	 to	 attempt	 to	 capture	 gene	 promoter	 and	 3’	 UTR	 regulatory	 elements.	 This	
results	in	a	Z	statistic	and	corresponding	p-value	(fixed	effects	estimate	after	permutations)	per	
gene	adjusted	for	LD,	or	the	raw	SNP	p-value	 in	the	case	of	only	one	SNP	being	mapped	to	a	
gene	 (Supplementary	Table	S1).	These	statistics	are	subsequently	 fed	 into	 the	gsa.pl	 script	 to	
combine	p-values	of	the	genes	per	pathway	(Supplementary	Table	S2).	The	SNP2Gene	mapping	
file	was	constructed	to	contain	all	protein	coding	genes	in	hg19	build	with	at	least	one	SNP	in	
PGC2	(19,492	genes).	To	assess	LD	structure	we	used	the	1000	Genomes	Phase	1.v3	data	after	
liftover	 to	 hg19	 and	 lightly	 pruned	 with	 a	 R2=0.9	 threshold	 using	 Priority	 Pruner	
(http://prioritypruner.sourceforge.net),	 prioritizing	 significant	 SNPs	 within	 the	 PGC2	 SCZ	 SNP	
results.	 The	 top	 resulting	 pathways	 were	 inspected	 for	 presence	 of	 gene-clusters,	 and,	 if	
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detected	 those	 drug	 gene	 sets	 were	 rerun	 with	 the	 entire	 gene	 cluster	 represented	 as	 one	
gene.		
With	 the	aim	of	validation,	 the	 INRICH	algorithm	 (Lee	et	al.	2012)	was	also	 run	using	a	 fuzzy	
border	option	(5’	35kb,	3’	10kb)	and	PGC2	SNP	data	clumped	according	to	protocol	for	the	top	
three	pathways.	Finally,	we	compiled	a	list	of	100	psychoactive	drugs	prescribed	for	SCZ,	MDD,	
BPD,	 ADHD	 or	 ASD	 and	 looked	 up	 corresponding	 FORGE	 p-values	 in	 our	 pathway	 results	
(Supplementary	table	S3).		
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Results		
Using	the	FORGE	algorithm	(Pedroso	et	al.	2012;	Pedroso	et	al.	2015)	we	combined	p-values	per	
gene	for	genes	with	5’	35kb,	3’	10kb	borders.	Results	are	given	 in	Table	S1.	Subsequently	we	
combined	p-values	for	genes	per	gene-set.	This	resulted	in	1,056	nominally	significant	pathways	
(139	with	unique	gene	content)	that	are	given	in	Table	S2.	The	significance	threshold	required	
to	 set	 the	 family	 wise	 error	 rate	 (FWER)	 significance	 threshold	 for	 5%	 is	 uncorrected	
p=0.0001196	using	matrix	 spectral	decomposition	 to	derive	 the	number	of	 independent	 tests	
(n=417,	see	Methods).	After	correction	 for	gene	clusters	no	single	drug	exceeded	experiment	
wide	significance	(corrected	p<0.05).	However,	three	known	schizophrenia	drugs	showed	highly	
ranked	 suggestive	 pathways	 and	 their	 gene	 content	 are	 listed	 in	 Table	 1.	 Of	 these,	
trifluoperazine	and	metoclopramide	also	 reach	nominal	 significance	 in	 INRICH	 (p=0.02),	while	
neratinib	is	non-significant	in	INRICH	results	(p=0.29).	
We	 then	 examined	 drugs	 commonly	 prescribed	 for	 SCZ,	 MDD,	 BPD,	 ADHD	 and	 ASD	
(Supplementary	 Table	 S3).	 We	 find	 that	 41	 of	 these	 drugs	 are	 represented	 in	 our	 pathway	
results,	with	22	(non-exclusively)	prescribed	for	SCZ.		7	out	of	41	drugs	reach	a	p-value	<0.05.	Of	
these,	 5	 (71%,	 Fisher’s	 exact	p=0.42)	 are	 prescribed	 for	 SCZ	 (trifluoperazine,	 chlorpromazine,	
fluphenazine,	 pimozide	 and	 aripiprazole	 (the	 latter	 also	 prescribed	 for	 BPD)),	 1	 for	 ADHD	
(bupropion)	and	1	for	ADHD	and	MDD	(amitriptyline).		
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Discussion		
The	aim	of	the	present	study	is	to	identify	potential	drug	repositioning	opportunities	and	clues	
to	novel	treatment	in	schizophrenia	by	interrogating	genome-wide	association	data	with	gene-
sets	derived	from	knowledge	of	the	pharmacological	action	of	drug.	The	development	of	new	
pharmaceutical	 medicines	 is	 a	 long,	 complex	 and	 expensive	 process,	 with	 about	 14	 years	
required	 to	 take	 a	 new	molecular	 entity	 to	market	 (Pammolli	 et	 al.	 2011).	 Two	 of	 the	most	
costly	aspects	are	the	identification	of	novel	small	molecules	with	drug-like	properties	and	good	
pharmacological	and	safety	profiles	 through	 iterative	medicinal	 chemistry,	and	assessment	of	
human	 safety	 and	 efficacy	 in	 clinical	 trials.	However	 the	 attrition	 rate	 of	 compounds	 in	 drug	
development	 is	 high	 with	 the	 predominant	 reason	 for	 failure	 in	 clinical	 trials	 not	 toxicity	 or	
pharmacology,	 but	 lack	of	 efficacy,	 a	 result	 of	 inadequate	 target	 validation:	 even	 though	 the	
drug	acts	on	the	target	in	the	desired	way,	it	does	not	alter	the	disease	process	(Bunnage	et	al.	
2015).	Thus	 there	 is	a	growing	pool	of	highly	characterized	 investigational	compounds,	which	
have	known	safety	and	pharmacology	profiles	but	no	medicinal	use.	These	have	been	making	
their	way	 into	 drug	 repositioning	 efforts	 (Frail	 et	 al.	 2015).	 There	 are	 some	 classical	 success	
stories	 in	drug	 repositioning,	 including	 the	erectile	dysfunction	drug	 sildenafil,	 an	 inhibitor	of	
PDE5	originally	developed	for	the	treatment	of	coronary	artery	disease	by	Pfizer	in	1980s	(Shim	
and	Liu	2014).		
However,	 there	 are	 a	 number	 of	 difficulties	 that	 need	 to	 be	 overcome	 for	 successful	 drug	
repositioning.	Firstly,	the	available	chemical	space	is	very	large	(Reymond	et	al.	2010;	Reymond	
2015)	 and	 the	proportion	 taken	up	by	 the	 existing	 set	 of	 preclinical	 or	 clinical	 compounds	 is	
very	 small.	 Secondly	 even	 if	 one	 is	 able	 to	match	 a	 drug	with	 a	 target	 implicated	 in	 a	 given	
disease,	considerable	resources	and	time	will	still	be	required	to	move	the	drug	 into	the	new	
indication,	depending	on	the	level	of	development	it	has	reached.	Thirdly,	for	a	brain	disorder	
such	as	 schizophrenia,	 the	drug	would	 also	need	 sustained	bioavailability	 in	 the	brain,	which	
will	not	often	be	the	case,	and	some	optimization	will	therefore	be	required.		
Despite	 these	 caveats,	 there	 is	 increasing	 effort	 in	 this	 area	 because	 of	 developments	 in	
methodology	and	the	availability	of	data,	together	with	the	promise	that	pre-clinical	and	clinical	
compounds	have	for	shortening	the	drug	development	process	and	providing	new	therapeutic	
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leads	(Shineman	et	al.	2014;	Shameer	et	al.	2015).	The	topic	of	the	present	study,	in	silico	drug	
repositioning	uses	publically	available	data	on	drugs	in	combination	with	bioinformatics	tools	to	
systematically	 identify	 interactions	 between	 compounds	 and	 targets	 (Dubus	 et	 al.	 2009;	
Wilkinson	and	Pritchard	2015),	in	our	case	generated	using	disease	genetics.	This	approach	has	
the	 potential	 to	 efficiently	 identify	 compounds	 for	 target	 validation	 studies	 and	 reduce	 the	
time-to-market.	
For	each	 individual	drug	we	created	a	gene-set	using	the	ChEMBL	database	resulting	 in	9,389	
(2,496	 with	 unique	 gene	 content)	 gene-sets	 that	 are,	 in	 essence,	 drug	 signatures	 based	 on	
known	pharmacological	properties.	We	assessed	the	significance	of	these	gene	sets	in	the	PGC2	
Schizophrenia	 GWAS	 summary	 statistics	 (Ripke	 et	 al.	 2014)	 to	 identify	 drugs	 and	 molecules	
showing	increased	evidence	in	the	genetic	data.		
We	found	1,056	nominally	significant	pathways	(139	with	unique	gene	content).	The	top	gene	
sets	 include	 the	 gene	 target	 sets	 of	 several	 plausible	 and	 several	 novel	 compounds.	A	 set	 of	
three	 drugs	 and	 compounds	 were	 suggestively	 associated	 (p<0.001196).	 The	 first	 was	
Metoclopramide,	 is	 a	 typical	 antipsychotic	 of	 the	 phenothiazine	 class	 currently	 used	 an	 anti-
nausea	medication.	The	CheMBL	 targets	of	Metoclopramide	are	ACHE,	CYP2D6,	DRD2,	DRD3,	
HTR3A,	 HTR3B	 of	 which	 DRD2	 shows	 GWAS	 association	 with	 schizophrenia,	 and	 the	
HTR3A/HTR3B	 locus	 shows	 association	 with	 SNPs	 with	 GWAS	 p<5x10-5).	 The	 third	 drug,	
Trifluoperazine	 (also	 known	 as	 the	 antipsychotic	 Stelazine)	 is	 also	 a	 D2	 agonist	 with	 P-
glycoprotein	 (P-gp)	 blocking	 activity.	 P-gp	 is	 encoded	 by	 the	 ABCB1	 gene	 which	 shows	 sub-
GWAS	 association	 (best	 SNP	 p	 =	 4x10-7)	 with	 schizophrenia	 (Ripke	 et	 al.	 2014).	 In	 addition,	
Neratinib,	 the	 second	 ranked	 drug,	 is	 a	 tyrosine	 kinase	 inhibitor	 under	 investigation	 for	 the	
treatment	breast	cancer	and	other	solid	tumours	with	a	very	large	spectrum	of	activity	against	
kinases,	 notably	 including	 multiple	 kinases	 within	 loci	 showing	 GWAS	 significant	 association	
with	 schizophrenia	 (FES,	PRKD1,	PAK6,	PTK2B,	TIE1)	 (Ripke	et	al.	2014)	However,	with	 such	a	
promiscuous	kinase,	it	is	difficult	to	draw	conclusions	on	precise	therapeutic	leads.	
A	set	of	nicotinic	compounds	just	failed	to	reach	suggestive	significance	after	for	the	effects	on	
statistics	of	the	CHRNA	gene	cluster	on	chromosome	15.	Top	amongst	these	compounds	were	
Altinicline	 (SIB-1508Y;	 (S)-(2)-5-ethynyl-3-(1-methyl-2-pyrrolidinyl)pyridine	 HCl),	 a	 neural	
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nicotinic	acetylcholine	receptor	(nAChR)	agonist	that	displaces	nicotine,	with	high	selectivity	for	
the	 α4β2	 subtype,	 and	 Dihydro-Beta-Erythroidine,	 a	 competitive	 nicotinic	 acetylcholine	
receptor	antagonist	with	moderate	selectivity	 for	 the	neuronal	α4	 receptor	 subunit.	Nicotinic	
acetylcholine	 receptors	 are	 well-established	 therapeutic	 targets	 in	 CNS	 disorders,	 including	
schizophrenia	where	agonists,	partial	agonists,	or	PAMs	 for	α7	nAChRs	or	partial	agonists	 for	
α4β2	nAChRs	have	been	developed	(Dineley	et	al.	2015).	The	nAChR	partial	agonist,	varenicline,	
improves	cognition	 in	schizophrenic	patients	(Hong	et	al.	2011;	Wing	et	al.	2013).	The	rate	of	
tobacco	use	among	schizophrenic	patients	is	very	high	and	indeed	nicotine	has	been	proposed	
to	ameliorate	some	of	the	sensory	deficits	in	schizophrenia	(Leonard	et	al.	2002).	The	15q13.3	
region	 has	 been	 implicated	 in	 schizophrenia	 before	 with	 rare	 microdeletions	 being	 more	
prevalent	 in	patients	 (Stefansson	et	al.,	 2008;	 International	 Schizophrenia	Consortium,	2008).	
Even	though	the	current	analysis	was	limited	to	common	variation,	the	analysis	still	indicated	a	
nominally	significant	signal	in	the	CHRNA	gene	cluster.	
What	was	striking	was	the	enrichment	for	known	therapeutic	and	mechanisms	of	action	among	
the	 top	 hits.	 This	 has	 also	 been	 described	 in	 a	 recent	 paper,	where	 authors	 focused	 on	 SCZ	
GWAS	hits	above	a	certain	significance	threshold	(Lencz	and	Malhotra	2015)	or	when	examining	
both	 rare	 and	 common	 variation	 (Ruderfer	 et	 al.	 2016).	 What	 sets	 our	 approach	 apart	 is	 a	
genome	wide	approach,	by	which	we	also	 identified	other	possible	drug	targets.	Some	of	the	
compounds	 identified	 by	 this	 approach	 may	 provide	 clues	 to	 novel	 treatment	 strategies	 in	
multi-target	 drug	 development	 or	 potentially	 be	 repurposed	 for	 the	 treatment	 of	
schizophrenia.	 However,	 while	 GWAS	 can	 provide	 lists	 of	 genes	 from	within	 associated	 loci,	
which	 can	 be	 used	 to	 identify	 potential	 drug	 targets,	 it	 does	 not	 provide	 a	 therapeutic	
hypothesis,	i.e.	whether	an	agonist	or	antagonist	is	required	for	a	particular	protein	target.	This	
is	especially	important	for	multi-target	drug	development	where	different	modalities	may	exist	
for	different	targets	within	a	multi	target	set.	Therefore,	further	experimental	data	is	required	
for	each	potential	target	on	 its	alteration	and	role	 in	disease	and	finally	target	validation	that	
will	tell	us	whether	manipulation	will	alter	disease.		
Additional	data	on	the	functional	effects	of	variants	 is	needed	to	ensure	that	the	direction	of	
effects	of	drugs	is	in	the	therapeutic	direction.	Secondly,	the	actions	of	these	drugs	are	on	a	set	
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of	individual	targets,	but	in	reality	they	may	act	on	a	disease	network,	so	an	understanding	of	
their	 concerted	 effect	 on	 disease	 biology	 may	 be	 needed,	 for	 example	 by	 analysis	 of	 their	
biological	effects	on	gene	networks	in	disease	models.	It	may	be	possible	to	circumvent	these	
approaches	by	performing	direct	proof-of-concept	studies	in	humans	where	drugs	are	known	to	
be	 safe	 in	 man,	 or	 at	 least	 have	 toxicology	 and	 side-effect	 profiles	 that	 are	 acceptable	 to	
patients	 with	 schizophrenia.	 Alternatively,	 where	 a	 drug	 is	 commonly	 prescribed,	 is	 brain	
penetrant	and	has	 sufficient	affinity	 for	 the	desired	 target,	pharmaco-epidemiological	 studies	
could	 be	 performed	 to	 see	 if	 there	 is	 a	 efficacy	 signal,	 such	 as	 those	 performed	 for	 calcium	
channel	blockers	and	Parkinson’s	disease	(Becker	et	al.	2008).	
	
Our	approach	is	essentially	a	drug	repositioning	and	molecule	drug	discovery	method	for	large	
scale	 genetic	 data,	 i.e.	 a	 “systematic	 or	 targeted	 evaluation	 of	 pharmaceutical	 compound	
libraries	or	compound	to	identify	new	indications	for	diseases	other	than	the	primary	diseases	
for	 which	 the	 drug	 was	 originally	 designed”	 (Chong	 and	 Sullivan	 2007;	 Dudley	 et	 al.	 2010;	
Collins	2011;	Shameer	et	al.	2015).	The	drug-pathway	gene	sets	we	 identified	act	on	multiple	
gene	 products	 identified	 by	 GWAS	 of	 schizophrenia,	 and	 thus	 may	 target	 the	 underlying	
aetiology	 of	 disease.	 The	 drugs	 we	 identified	 with	 formal	 or	 suggestive	 significance	 include	
antipsychotic	 medications	 acts	 on	 the	 dopamine	 D2	 receptor	 DRD2	 among	 other	 targets.	
Further	 down	 nominally	 significant	 there	 are	 multiple	 highly	 ranked	 drugs	 and	 molecules	
affecting	 neural	 nicotinic	 receptors,	 calcium	 channels,	 and	 opioid	 receptors.	 Notably,	 all	 of	
which	(except	DRD2)	have	previously	been	considered	as	therapeutic	targets	for	schizophrenia	
but	have	never	been	properly	tested.	This	type	of	repositioning	study,	and	its	refinements,	may	
provide	the	impetus	to	test	these	mechanisms	in	the	clinical	treatment	of	schizophrenia.	
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